Base structurelle de la signalisation hormonale FGF

Nature (2023)Cite this article

2745 Accesses

6 Altmetric

Metrics details

α/βKlotho coreceptors simultaneously engage fibroblast growth factor (FGF) hormones (FGF19, FGF21 and FGF23)1,2 and their cognate cell-surface FGF receptors (FGFR1–4) thereby stabilizing the endocrine FGF–FGFR complex3,4,5,6. However, these hormones still require heparan sulfate (HS) proteoglycan as an additional coreceptor to induce FGFR dimerization/activation and hence elicit their essential metabolic activities6. To reveal the molecular mechanism underpinning the coreceptor role of HS, we solved cryo-electron microscopy structures of three distinct 1:2:1:1 FGF23–FGFR–αKlotho–HS quaternary complexes featuring the ‘c’ splice isoforms of FGFR1 (FGFR1c), FGFR3 (FGFR3c) or FGFR4 as the receptor component. These structures, supported by cell-based receptor complementation and heterodimerization experiments, reveal that a single HS chain enables FGF23 and its primary FGFR within a 1:1:1 FGF23–FGFR–αKlotho ternary complex to jointly recruit a lone secondary FGFR molecule leading to asymmetric receptor dimerization and activation. However, αKlotho does not directly participate in recruiting the secondary receptor/dimerization. We also show that the asymmetric mode of receptor dimerization is applicable to paracrine FGFs that signal solely in an HS-dependent fashion. Our structural and biochemical data overturn the current symmetric FGFR dimerization paradigm and provide blueprints for rational discovery of modulators of FGF signalling2 as therapeutics for human metabolic diseases and cancer.

The mammalian fibroblast growth factor (FGF) family comprises 18 β-trefoil homology-domain-containing polypeptides arranged into five paracrine subfamilies and one endocrine subfamily7. Paracrine subfamilies govern multiple events during embryonic development8 whereas endocrine subfamily members (FGF19, FGF21 and FGF23) are hormones that regulate bile acid, lipid, glucose, vitamin D and mineral ion homeostasis1,4,9,10. FGF hormones are promising targets for the treatment of a spectrum of metabolic diseases, including type II diabetes, obesity, non-alcoholic steatohepatitis, primary biliary cirrhosis, bile acid diarrhoea, renal phosphate wasting disorders and chronic kidney disease2,11,12,13,14,15,16,17,18,19. FGFs mediate their actions by binding, dimerizing and thereby activating single-pass transmembrane FGF receptor tyrosine kinases (FGFR1–4)20,21. The extracellular region of a prototypical FGFR contains three immunoglobulin (Ig)-like domains (D1, D2 and D3). D2, D3 and the short D2–D3 linker are necessary and sufficient for ligand binding and receptor dimerization. In FGFR1–FGFR3, alternative splicing of two mutually exclusive exons (termed ‘b’ and ‘c’) alters the composition of major ligand-binding sites within the D3 domains of these three FGFRs, effectively expanding the number of principal FGFR isoforms to seven (that is, FGFR1b–3b, FGFR1c–3c and FGFR4)22,23,24.

Paracrine FGFs depend on heparan sulfate (HS) glycosaminoglycans as a mandatory coreceptor to stably bind and dimerize their cognate FGFRs. HS are linear glycan chains of HS proteoglycans (HSPGs) that are abundantly expressed in the extracellular matrix of all tissues25. According to the crystal structure of the 2:2:2 FGF2–FGFR1c–HS dimer, HS concurrently engages the HS binding sites of paracrine FGF and FGFR, thereby enforcing FGF–FGFR proximity. In doing so, HS (1) enhances 1:1 FG–FGFR binding affinity; and (2) fortifies interactions between two 1:1 complexes to give rise to two-fold symmetric 2:2 dimers26. Extracellular FGFR dimerization promotes the formation of a thermodynamically weak asymmetric complex of the intracellular kinase domains27 that mediates (A)-loop tyrosine transphosphorylation and hence kinase activation and intracellular signalling.

The HS binding sites of FGF hormones diverge both compositionally and conformationally from those of paracrine FGFs, dramatically weakening their affinity for HS28. Consequently, FGF hormones avoid entrapment by the HSPGs in the extracellular matrix and can enter the circulation. Moreover, FGF hormones have weak affinity for FGFRs28,29 owing to substitutions of their key receptor binding residues. While these structural and biochemical idiosyncrasies confer hormonal mode of action, they render HS insufficient for endocrine FGF to bind FGFR and induce receptor dimerization. Indeed, to offset these deficiencies, FGF hormones have evolved an absolute dependency on αKlotho or βKlotho as an additional coreceptor for signalling. α- and βKlotho are single-pass transmembrane proteins with a large extracellular domain comprising two tandem glycosidase-like domains (KL1 and KL2), and a short intracellular domain3,5. αKlotho (or βKlotho) coreceptor simultaneously binds the FGF hormone and its cognate FGFR, thereby enforcing binding of endocrine FGF to FGFR. Klotho coreceptors have unique FGF hormone and FGFR binding specificities which ultimately dictate FGFR binding specificity and target tissue/organ selectivity of endocrine FGFs. αKlotho binds exclusively to FGF23 (ref. 30) whereas βKlotho binds both FGF19 and FGF21 (refs. 31,32,33,34). With respect to FGFR interaction, αKlotho and βKlotho show shared specificity for FGFR1c and FGFR4 but neither recognizes the ‘b’ splice isoforms of FGFR1–3. However, they display opposite specificity towards FGFR2c and FGFR3c with αKlotho binding FGFR3c but not FGFR2c, while βKlotho binds FGFR2c but not FGFR3c (ref. 35).

The coreceptor mechanism of αKlotho in FGF23 signalling was illuminated by the crystal structure of a ternary complex comprising FGF23, the FGFR1c ligand-binding domain6 and the soluble ectodomain of αKlotho (a naturally occurring isoform produced via shedding of the transmembrane form)36,37. In the structure, the long α1β1 loop (denoted receptor binding arm (RBA)) extends from the KL2 domain of αKlotho and clasps a hydrophobic groove in the D3 domain of FGFR (a conserved hallmark of FGFR1c–3c and FGFR4), while a large cleft at the junction between KL1 and KL2 embraces FGF23's long C-tail. In doing so, αKlotho enforces FGF23–FGFR proximity and complex stability. As to the role of HS, we previously postulated that HS enables two 1:1:1 FGF23–FGFR–αKlotho complexes to assemble into a symmetric 2:2:2:2 FGF23–FGFR–αKlotho–HS quaternary signalling unit reminiscent of 2:2:2 paracrine FGF–FGFR–HS dimers6. To establish the mechanism underlying dual coreceptor (that is, αKlotho and HS) dependent FGFR dimerization/activation by FGF hormones, we solved cryogenic electron microscopy (cryo-EM) structures of all three physiologically possible FGF23–FGFR–αKlotho–HS quaternary complexes. Unexpectedly, these structures, supported by comprehensive cell-based data, reveal that HS fortifies interactions of FGF23 and its primary FGFR within a 1:1:1 FGF23–FGFR–αKlotho with a secondary lone FGFR, thereby inducing asymmetric receptor dimerization and activation. Notably, the asymmetric mode of receptor dimerization is generalizable to paracrine FGFs, which thus overturns our current symmetric model for FGFR dimerization and activation26.

We prepared 1:1:1:1 quaternary mixtures of full-length mature human FGF23, the extracellular ligand-binding portions (that is, encompassing D2 and D3 domains) of three human cognate FGFRs of FGF23 (that is, FGFR1c, FGFR3c and FGFR4), whole ectodomain of human αKlotho coreceptor and a fully sulfated heparin dodecasaccharide (hereafter, referred to as HS). The three resulting quaternary complexes (that is, FGF23–FGFR1c–αKlotho–HS, FGF23–FGFR3c–αKlotho–HS and FGF23–FGFR4–αKlotho–HS) were isolated by size-exclusion chromatography (SEC) and were used directly for vitrification, cryo-EM image collection and structure determination (Extended Data Fig. 1, Extended Data Table 1 and Supplementary Fig. 2). Contrary to our prediction, all three cryo-EM structures reveal identical asymmetric 1:2:1:1 FGF23–FGFR–αKlotho–HS quaternary assemblies in which HS enables a 1:1:1 FGF23–FGFR–αKlotho ternary complex to recruit a lone FGFR chain (termed FGFRS to differentiate it from the ‘primary’ receptor FGFRP within the ternary complex) (Fig. 1). At the membrane distal end of each quaternary complex, HS engages in tripartite interactions with juxtaposed HS binding sites of FGF23, FGFRP and FGFRS (Fig. 2a). In doing so, HS augments interactions of FGF23 and FGFRP from the FGF23–FGFRP–αKlotho ternary complex with the FGFRS chain, and thus induces receptor (that is, FGFRP–FGFRS) dimerization (Fig. 3a). Notably, the proximity and orientation (perpendicular to plasma membrane) of C-terminal ends of FGFR chains (approximately 25 Å apart) acquiesces with the formation of an A-loop transphosphorylating asymmetric dimer of intracellular kinase domain27 (Extended Data Fig. 2a). Although αKlotho does not directly engage FGFRS, it presides over the FGFRS recruitment by stabilizing the FGF23–FGFRP complex. Without αKlotho's assistance, HS cannot independently generate a stable FGF23–FGFRP complex that is necessary to recruit a secondary FGFRS. Indeed, cell-based experiments confirm that FGF23 signalling is strictly αKlotho dependent (Extended Data Fig. 2b). The conformation of the FGF23–FGFRP–αKlotho ternary complex within the 1:2:1:1 FGF23–FGFR–αKlotho–HS quaternary assemblies is similar to that of the X-ray structure of HS-free FGF23–FGFR–αKlotho ternary complex (root mean square deviation (RMSD) of only 1.16 Å, Extended Data Fig. 2c)6. However, the FGFRS component of the quaternary complex adopts a distorted conformation that is incompatible with ligand binding, which thus explains the distinct asymmetry of the quaternary complex (Supplementary Fig. 4).

Overall view of the cryo-EM reconstructions of FGF23–FGFR1c–αKlotho–HS (a), FGF23–FGFR3c–αKlotho–HS (b) and FGF23–FGFR4–αKlotho–HS (c) quaternary complexes displayed at threshold levels of 0.6, 0.45 and 0.5, respectively. The quaternary complex is shown in two different orientations related by a 180° rotation along the vertical axis. FGF23 is coloured in orange, αKlotho is shown in deep blue and HS is in magenta. Primary receptor (FGFRP) and secondary receptor (FGFRS) are shown in green and light blue in the FGF23–FGFR1c–αKlotho–HS complex, in tan and pink in the FGF23–FGFR3c–αKlotho–HS complex and in gold and light yellow in the FGF23–FGFR4–αKlotho–HS complex. Two tandem glycosidase-like domains (KL1 and KL2) and RBA of αKlotho are labelled. The relevance of the extra weak density (in grey) seen in all three 1:2:1:1 quaternary complexes is discussed in Supplementary Fig. 3.

a, FGF23–FGFR1c–αKlotho–HS asymmetric quaternary complex displayed as a hybrid of cartoon (FGF23, FGFR and HS) and surface (αKlotho) in the same orientation as in Fig. 1a (left). b, Expanded view of the boxed region in panel a showing tripartite interaction of HS with FGF23, FGFRP and FGFRS. HS interacting residues are shown as sticks and labelled. Hydrogen bonds in this figure and subsequent figures are represented as black dashed lines. Throughout the figures, nitrogen, oxygen and sulfur atoms are coloured blue, red and yellow, respectively. All structural illustrations were made using Pymol (v.2.5.2). c, L6-FGFR1cWT, L6-FGFR1cΔHBS1, L6-FGFR1cΔHBS1 or L6-FGFR1cΔHBS1+2 were cotreated with 20 nM 1:1 mixture of FGF23WT + αKlotho or FGF23R48A/R140A (FGF23ΔHBS) + αKlotho (in the case of L6-FGFR1cWT only) or left untreated. Total cell lysates were immunoblotted with an anti-pY656/Y657–FGFR, anti-pY783-PLCγ1, anti-pY196-FRS2α, anti-pT202/Y204-ERK and anti-β-tubulin antibody (loading control). d, Loss in the abilities of FGF23ΔHBS and FGFR1cΔHBS mutants to induce formation of the FGF23–FGFR1c–αKlotho–HS quaternary complex as visualized by PLA. Red spots signify FGF23–FGFR1c–αKlotho–HS quaternary complexes on the cell surface and blue-stained large circles/ovals are cell nuclei. Note that, compared with FGF23WT-treated L6-FGFR1cWT cells, there are far fewer red spots in FGF23ΔHBS-treated L6-FGFRcWT and FGF23WT-treated L6-FGFR1cΔHBS cells. Scale bar, 10 μm. Immunoblotting (c, normalized against wild-type FGFR1 and FGF23, n = 3 biologically independent experiments) and PLA (d, n = 6 randomly chosen microscope fields from two biologically independent experiments) were quantitated as described in the Methods section and are presented as the mean ± standard deviation. P values were determined by two-way ANOVA followed by Tukey's multiple comparisons post hoc test.

Source data

a, Representation of the FGF23–FGFR1c–αKlotho–HS complex structure as a mix of cartoon (FGF23 and FGFR) and surface (αKlotho). View is related to that in Fig. 1a (right) by 90° rotation along the vertical axis. Contact sites 1 and 2 of the FGFR1cP–FGFR1cS dimer interface are boxed in blue and black, respectively. Note that αKlotho does not directly participate in recruiting FGFR1S. Left, magnified view of site 1 involving D2 domain of FGFR1cP and D2, D2–D3 linker and D3 of FGFR1cS. Right, close-up view of site 2 between D3 domains of FGFR1cP and FGFR1cS. Side chains of the interacting residues are shown as sticks. Selected secondary structure elements are labelled. Hydrophobic contacts are highlighted as a semitransparent surface. A Cu2+ ion (orange sphere) is coordinated by analogous histidine residues from FGFR1cP and FGFR1cS. Cu2+ assignment was based on a previous publication implicating specific Cu2+ interactions with extracellular domains of FGFRs39. Cu2+ ions probably derive from cell culture media (DMEM and DME/F12) used to grow HEK293S GnTI− cells that secrete minimally glycosylated FGFR ectodomains. b–d, Immunoblot analyses of whole cell extracts probed as in Fig. 2c from unstimulated or FGF23 (20 nM) and αKlotho (20 nM) costimulated FGFR1c (b), FGFR3c (c) or FGFR4 (d) expressed L6 cell lines. Immunoblotting data were quantitated as described in the Methods section and are presented as the mean ± standard deviation. Data normalized against wild-type FGFR and FGF23, n = 3 biologically independent experiments. P values were determined by two-way ANOVA followed by Tukey's multiple comparisons post hoc test.

Source data

FGF23–HS interactions are mediated by three residues (Arg48, Arg140 and Tyr154) from the atypical HS binding site within the core of FGF23 (Fig. 2b). Compared with FGF23–HS contacts, HS interacts more extensively with HBS in the D2 domains of the two FGFR chains, involving residues Lys177, Lys207, Arg209 and Ser214 of FGFR1cP and Lys175, Lys177, Val208, Arg209 and Thr212 of FGFR1cS (Fig. 2b). To validate the physiological importance of three-way interactions of HS with FGF23, FGFR1cP and FGFR1cS for the induction of receptor (that is, FGFRP–FGFRS) dimerization, we introduced an R48A/R140A double mutation into FGF23 (FGF23ΔHBS) and K175Q/K177Q and K207Q/R209Q double mutations (FGFR1cΔHBS1 and FGFR1cΔHBS2) separately or in combination (K175Q/K177Q/K207Q/R209Q termed FGFR1cΔHBS1+2) into the full-length FGFR1c. Wild-type FGFR1c (FGFR1cWT) and its mutated variants were stably expressed on the surface of rat skeletal myoblast cells (L6), an αKlotho- and FGFR-deficient cell line. Endoglycosidase H (Endo H) and Peptide:N-glycosidase F (PNGase F) treatment of cell lysates followed by immunoblot analysis with FGFR-specific antibodies showed that mutated FGFR1c variants contain complex sugars, which implies that they reside on the cell surface (Extended Data Fig. 3a). Equal homogeneity/quantity of FGF23WT and FGF23ΔHBS samples was verified by SDS–PAGE (Supplementary Fig. 2d). Cotreatment with FGF23WT and soluble αKlotho of L6-FGFR1cWT led to robust FGFR1c activation/signalling as measured by phosphorylation of FGFR1c on A-loop tyrosines, its two direct substrates PLCγ1 (on the regulatory Y783) and FRS2α (on the Grb2 recruitment site Y196) and subsequent activation of a RAS–mitogen-activated protein kinase (MAPK) pathway as monitored by extracellular signal-regulated kinase (ERK) phosphorylation on T202/Y204. In contrast, both FGFR1cΔHBS1 and FGFR1cΔHBS2 double mutants suffered major losses in their ability to induce FGF23 signalling, and the FGFR1cΔHBS1+2 quadruple mutant became totally silent (Fig. 2c). Likewise, FGF23ΔHBS was significantly retarded in its ability to activate L6-FGFR1cWT in the presence of soluble αKlotho. FGFR activation/signalling data were mirrored by proximity ligation assay (PLA) data. Specifically, cotreatment with FGF23WT and αKlotho led to appearance of copious and intense punctate fluorescent signals on the surface of the L6-FGFR1cWT cell line. In contrast, there were far fewer fluorescent signals on the surface of FGFR1cΔHBS1, FGFR1cΔHBS2 and FGFR1cΔHBS1+2 cell lines upon cotreatment. Similarly, markedly fewer fluorescent dots were present on the surface of the L6-FGFR1cWT cell line when cotreated with FGF23ΔHBS and soluble αKlotho (Fig. 2d). These cell-based data confirm the indispensability of FGF23–HS and FGFR1c–HS contacts in inducing formation of a FGF23–FGFR1c–αKlotho–HS quaternary cell-surface signalling complex. Consistent with the 1:2:1:1 FGF23–FGFR–αKlotho–HS stoichiometry in the cryo-EM structures, size-exclusion chromatography–multi-angle light scattering experiments showed that the FGF23–FGFR1c–αKlotho–HS quaternary complex migrates as a single species with a calculated molecular mass of approximately 220 kDa, which matches closely the theoretical value for a 1:2:1:1 FGF23–FGFR1c–αKlotho–HS (215 kDa) (Supplementary Fig. 2e).

All three subdomains (that is, D2, D2–D3 linker and D3) of both FGFRP and FGFRS chains take part in recruitment of FGFRS to the ternary complex and hence in promoting receptor dimerization (Fig. 3a). The direct FGFRP–FGFRS contacts bury a modest solvent-exposed surface area (1542.6 Å2) and are preserved among the three cryo-EM structures. The FGFRP–FGFRS interface can be split into two sites (that is, sites 1 and 2). At site 1, residues from discontinuous loop regions (that is, βA’–βB and βE–βF loops) at the bottom (C-terminal) corner of D2 of FGFRP asymmetrically pack against D2, D2–D3 linker and D3 of the FGFRS (Fig. 3a). At site 2, a contiguous stretch of residues encompassing D2–D3 linker, βA strand, βA–βA’ loop and βB’ strand of D3, engage the corresponding region of the secondary receptor in a pseudo-symmetric fashion (Fig. 3a and Supplementary Table 1). Notably, the FGFRP–FGFRS interface traps two crucial ligand-binding residues of FGFRS, namely, Arg250 and Ser346, which further deprives FGFRS from ligand binding (Supplementary Fig. 4b).

We targeted site 2 of the FGFRP–FGFRS interface in each of the three quaternary complexes by introducing four different point mutations individually into full-length FGFR1c (E249A, R254A, I256A, Y280A), FGFR3c (E247A, R252A, I254A, Y278A) or FGFR4 (E243A, R248A, I250A, Y274A). In addition, we introduced a A170D/A171D/S219K triple mutation into FGFR1c to target site 1 of the FGFR1cP–FGFR1cS dimer interface (Fig. 3a) as the representative of the three quaternary complexes. Full-length FGFR1c, FGFR3c and FGFR4 variants along with their wild-type counterparts were stably expressed in L6 cells. As above, Endo H sensitivity was used to ensure that the mutations do not affect receptor glycosylation/maturation and cell-surface presentation (Extended Data Fig. 3b–d). Apart from the FGFR1cI256A and its corresponding FGFR4I250A mutant, all mutants showed comparable ratios of Endo H-resistant to total FGFR protein-like wild-type FGFRs. These data imply that only FGFR1cI256A and corresponding FGFR4I250A had reduced cell-surface expression. As in the case of the L6-FGFR1cWT cell line, cotreatment with FGF23 and soluble αKlotho of L6-FGFR3cWT and L6-FGFR4WT cell lines robustly stimulated FGFR signalling as detected by phosphorylation/activation of FGFRs and downstream PLCγ1/FRS2α/ERK signal transducers. In contrast, cells expressing mutated FGFR1c, FGFR3c and FGFR4 had diminished FGFR A-loop tyrosine phosphorylation and reduced PLCγ1, FRS2α and MAPK activation (Fig. 3b–d). It is unlikely that the impaired signalling by FGFR1cI256A and FGFR4I250A is solely due to reduced cell-surface expression because the glycosylation and cell-surface expression of the corresponding FGFR3cI254A is unaffected.

FGF23 also participates in recruiting FGFRS to the ternary complex and hence in buttressing FGFRP–FGFRS dimerization. These secondary FGF23–FGFRS contacts are mediated by both the rigid trefoil core and the flexible N terminus of FGF23. Specifically, the β8–β9 and β10–β12 loops within FGF23's trefoil core engage the βC–βD and βE–βF loops at the bottom edge (C-terminal) of the FGFRS D2 domain (Fig. 4a). In parallel, hydrophobic residues at the very distal end of the FGF23 N terminus extend from the FGF23–FGFRP–αKlotho complex and interact with a hydrophobic groove in the FGFRS D3 domain that corresponds to the D3 groove in FGFRP engaged by the RBA of αKlotho (Fig. 4a and Extended Data Fig. 4a). In doing so, the FGF23 N terminus is likely to discourage binding of another αKlotho to FGFRS and hence contributes to the quaternary complex asymmetry. When compared with the crystal structure of the HS-free 1:1:1 FGF23–FGFR–αKlotho complex, the N terminus of FGF23 displays a major conformational change in the 1:2:1:1 FGF23–FGFR–αKlotho–HS quaternary complex (Extended Data Fig. 4b–d). Notably, in all three cryo-EM structures, electron densities for the FGF23 N terminus are poorly defined, which implies that the FGF23 N terminus engages FGFRS D3 in a rather degenerate and flexible fashion (Fig. 1a–c and Extended Data Fig. 4e). Interactions of the FGF23 N terminus with FGFRS D3 were corroborated by a 300 ns all-atom molecular dynamics (MD) simulation of the FGF23–FGFR1c–αKlotho–HS complex (Extended Data Fig. 4f–i). Akin to the FGFRP–FGFRS interface, the FGF23–FGFRS interface (Supplementary Table 2) is also conserved among the three quaternary complexes and masks a rather modest surface exposed area (1668.6 Å2). Notably, the FGF23 N terminus and D3 of the FGFRS engage each other in the proximity of site 2 of the FGFRP–FGFRS interface (Fig. 4a). This implies that FGF23–FGFRS and FGFRP–FGFRS contacts act in concert to recruit FGFRS to the ternary complex and promote receptor dimerization (that is, FGFRP–FGFRS).

a, Cartoon representation of the FGF23–FGFR–αKlotho–HS structure in the same view as in Fig. 1a (right). Orange and black boxes signify the two contact regions between FGF23 and FGFRS, namely, FGF23core:FGFR1cS D2 domain (left, orange box) and FGF23NT:FGFR1cS D3 domain (right). b, L6-FGFR1cWT cells were treated with increasing concentrations of FGF23WT, FGF23ΔNT or FGF23ΔSRBS and whole cell lysates were probed as in Fig. 2. Equal homogeneity/quantity of FGF23WT, FGF23ΔNT and FGF23ΔSRBS samples was verified by SDS–PAGE (Supplementary Fig. 2d). c, Loss in the abilities of FGF23ΔNT and FGF23ΔSRBS mutants to induce FGF23–FGFR–αKlotho–HS quaternary complex formation (that is, receptor dimerization) relative to FGF23WT as assessed by PLA. Note that there are far fewer red spots in cells stimulated with FGF23 mutants relative to FGF23WT. d, L6-FGFR1cWT cells were treated with FGF23WT (40 nM) alone, FGF23WT (40 nM) mixed with FGF23ΔSRBS (40 nM) or FGF23ΔNT (40 nM) and whole cell extracts were probed with pFGFR antibodies. Scale bar, 10 μm. Immunoblotting (b and d, n = 3 biologically independent experiments) and PLA (c, n = 6 randomly chosen microscope fields from two biologically independent experiments) were quantitated as described in the Methods section and are presented as the mean ± standard deviation. P values were determined by two-way ANOVA followed by Tukey's multiple comparisons post hoc test.

Source data

Next, we studied the impact of interfering with the secondary FGF23–FGFRS contacts on formation of the 1:2:1:1 FGF23–FGFR–αKlotho–HS quaternary signalling complex. For this purpose, we generated two FGF23 variants: one lacking its first 12 N-terminal residues (that is, Y25 to W36; termed FGF23ΔNT), and the other harbouring a M149A/N150A/P151A triple mutation within the core region of the FGF23 (termed FGF23ΔSRBS). According to the cryo-EM structures, the M149A/N150A/P151A triple mutation and N-terminal truncation are predicted to abrogate secondary interactions of FGF23 with D2 and D3 domains of FGFRS, respectively, and hence impair FGF23 signalling (Fig. 4a). To test this, an L6 cell line co-expressing FGFR1cWT and transmembrane αKlotho was generated and exposed to increasing concentrations of FGF23WT, FGF23ΔNT or FGF23ΔSRBS. Receptor dimerization/activation efficacies of increasing concentrations of ligands were assessed by immunoblotting for FGFR A-loop tyrosine phosphorylation and by PLA (Fig. 4b,c). Comparison of dose–response curves showed that, at all concentrations, neither FGF23ΔNT nor FGF23ΔSRBS could reach the maximal activity (Emax) exerted by FGF23WT in both assays. Moreover, when combined with FGF23WT, both FGF23ΔSRBS and FGF23ΔNT acted as competitive antagonists producing a net decrease in FGFR1c activation (Fig. 4d). However, relative to FGF23ΔNT, FGF23ΔSRBS showed a greater loss in its dimerization/signalling capacity (Fig. 4b–d), which implies that the FGF23–FGFRS contacts mediated via the core of the FGF23 contribute more to the overall stability and functionality of the FGF23–FGFR1c–αKlotho–HS quaternary signalling complex than those mediated by FGF23 N terminus.

We devised a cell-based receptor complementation assay to interrogate the asymmetry of FGF23–FGFR–αKlotho–HS quaternary signalling complexes. Specifically, based on the distinct roles played by primary and secondary receptors in the asymmetric dimerization, we engineered two FGFR1c variants capable of acting exclusively either as the primary or secondary receptor. We reasoned that although these variants would be dysfunctional individually, they should complement each other and form a functional 1:2:1:1 quaternary complex in response to FGF 23 and αKlotho (Fig. 5a and Extended Data Fig. 5a,b). To generate a FGFR1c variant functioning exclusively as primary receptor, we introduced a I203E/S223E double mutation in its D2 domain. As mentioned above, these two residues in FGFR1cS engage in hydrophobic and hydrogen bonding contacts with residues in the core of the FGF23 (that is, FGF23–FGFR1cS interface, Fig. 4a), which are indispensable for recruitment of FGFR1cS to the ternary complex as implied by the severe loss of function of FGF23ΔSRBS (Fig. 4b,c). However, the corresponding residues in FGFR1cP are dispensable for quaternary complex formation and are solvent exposed (Extended Data Fig. 5b). Consequently, the resulting mutant FGFR1c (termed FGFR1cΔSLBS) is predicted to lose the ability to act as a secondary receptor but should retain the ability to serve as a primary receptor. To make an FGFR1c variant capable of acting solely as secondary receptor, we introduced a A167D/V248D double mutation into its D2 domain. The A167D/ V248D double mutation abrogates formation of highly conserved hydrogen and hydrophobic contacts between FGF23 and the FGFR1P D2 domain (Extended Data Fig. 5a,b). Thus, the resulting FGFR1cA167D/V248D mutant (termed FGFR1cΔPLBS) is predicted to lose the ability to function as a primary receptor (that is, form a ternary complex). However, FGFR1cΔPLBS should retain its ability to function as a secondary receptor because the corresponding residues in FGFR1cS do not play any role in the quaternary complex formation and are completely solvent exposed.

a, Schematic diagram showing that, in response to FGF23 and αKlotho cotreatment, FGFR1cΔSLBS and FGFR1cΔPLBS can complement each other and form a 1:1:1:1:1 FGF23–FGFR1cΔSLBS–FGFR1cΔPLB–αKlotho–HS asymmetric complex. b, Immunoblot analyses of whole extracts from untreated or FGF23- and αKlotho-cotreated L6 cell lines singly expressing FGFR1cWT, FGFR1cΔPLBS and FGFR1cΔSLBS or co-expressing FGFR1cΔSLBS with FGFR1cΔPLBS probed as in Fig. 2. c, Schematic diagram showing that FGF23, αKlotho and FGFR4ΔSLBS (serving as a primary receptor) form a ternary complex and recruit FGFR1cΔPLBS as a secondary receptor, in the presence of HS. d, FGF23- and αKlotho-cotreated L6 cell lines stably expressing FGFR4WT, FGFR4ΔSLBS alone or FGFR4ΔSLBS together with FGFR1cΔPLBS were analysed for FGFR activation/signalling using western blotting of total cell lysates as in Fig. 2. e, Schematic diagram showing that, in response to paracrine FGF1/4 and HS, FGFR1cΔSLBS and FGFR1cΔPLBS can complement each other and form 1:1:1:1 FGF–FGFR1cΔSLBS–FGFR1cΔPLBS–HS asymmetric signalling complexes. f, L6 cell lines expressing FGFR1cΔSLBS and FGFR1cΔPLBS individually or co-expressing them were treated with FGF1 (1 nM) and cell extracts were immunoblotted as in Fig. 2. g, Schematic diagram showing that FGF1, HS and FGFR4ΔSLBS (serving as primary receptor) form a stable complex which subsequently recruits FGFR1cΔPLBS as a secondary receptor. h, L6 cell lines expressing FGFR4WT or FGFR4ΔSLBS singly or co-expressing FGFR4ΔSLBS with FGFR1cΔPLBS were treated with FGF1 (1 nM) and cell extracts were immunoblotted as in Fig. 2. Experiments were performed in biological triplicates with similar results. CT, C terminus; NT, N terminus.

To perform the complementation assay, an L6 cell line co-expressing FGFR1cΔSLBS and FGFR1cΔPLBS (L6-FGFR1cΔSLBS + FGFR1cΔPLBS) was generated along with two control L6 cell lines individually expressing FGFR1cΔSLBS (L6-FGFR1cΔSLBS) and FGFR1cΔPLBS (L6-FGFR1cΔPLBS). These three cell lines and L6-FGFR1cWT (positive control) were exposed to a fixed concentration of FGF23 and soluble αKlotho for increasing time intervals. FGFR1c signalling was assessed by monitoring tyrosine phosphorylation of FGFR, PLCγ1 and FRS2α, and subsequent activation of MAPK pathway. Compared with the L6-FGFR1cWT cell line, there was negligible FGFR signalling in L6-FGFR1cΔPLBS or L6-FGFR1cΔSLBS cells (Fig. 5b), which implies that these variants on their own are unable to form signalling-competent quaternary complexes. In contrast, co-expression of FGFR1cΔSLBS with FGFR1cΔPLBS (Fig. 5b) resulted in robust activation of an FGFR signalling pathway. These data imply that FGFR1cΔSLBS can complement FGFR1cΔPLBS in forming a signalling-competent FGF23–FGFR1cΔSLBS–FGFR1cΔPLBS–αKlotho–HS quaternary complex, in which FGFR1cΔSLBS assumes the role of primary receptor while FGFR1cΔPLBS is adopted as the secondary receptor (Fig. 5a). Formation of an asymmetric FGF23–FGFR1cΔSLBS–FGFR1cΔPLBS–αKlotho–HS signalling complex was also validated by PLA (Extended Data Fig. 5c). Compared with L6-FGFR1cWT cells, FGF23 and αKlotho cotreatment failed to generate any fluorescent signals on the surface of L6-FGFR1cΔSLBS and L6-FGFR1cΔPLBS cells, which implies that FGFR1cΔSLBS and L6-FGFR1cΔPLBS variants alone fail to undergo receptor dimerization (that is, quaternary complex formation). In contrast, stimulation of L6-FGFR1cΔSLBS + FGFR1cΔPLBS co-expressing cells with FGF23 and αKlotho led to appearance of copious and intense florescent puncta, implying that FGFR1cΔSLBS and FGFR1cΔPLBS have complemented each other and assembled into an asymmetric FGF23–FGFR1cΔSLBS–FGFR1cΔPLBS–αKlotho–HS signalling complex.

As mentioned above, both FGFRP–FGFRS and FGF23–FGFRS interfaces are nearly invariant among the three quaternary complexes. This observation afforded us with another opportunity to interrogate the asymmetry of the complex. Specifically, we reasoned that a primary FGFR1cP should be able to pair with FGFR3c or FGFR4 as the secondary receptor to yield functional 1:2:1:1 FGF23–FGFR1c–FGFR3c–αKlotho–HS or FGF23–FGFR1c–FGFR4–αKloth–HS heterodimeric quaternary complexes (Fig. 5c). To test this possibility, we carried out a receptor complementation assay using an FGFR4 variant harbouring a double I197E/S217E mutation (termed FGFR4ΔSLBS)—corresponding to FGFR1cΔSLBS—as the primary receptor and FGFR1cΔPLBS as the secondary receptor. An L6 cell line co-expressing FGFR1cΔPLBS with FGFR4ΔSLBS (L6-FGFR1cΔPLBS + FGFR4ΔSLBS), along with control cell lines individually expressing FGFR4WT (L6-FGFR4WT) and FGFR4ΔSLBS (L6-FGFR4ΔSLBS) were derived. These cell lines were cotreated with FGF23 plus αKlotho, and quaternary signalling complex formation was examined by immunoblot analysis and PLA. As with FGFR1cΔSLBS and FGFR1cΔPLBS, FGFR4ΔSLBS also failed to be activated in response to FGF23 plus αKlotho cotreatment. However, robust activation of an FGFR signalling pathway took place in the L6-FGFR1cΔPLBS + FGFR4ΔSLBS co-expressing cell line (Fig. 5d). The cell signalling data were mirrored by the PLA (Extended Data Fig. 5c). Specifically, inconsequential florescent signal was present on the surface of L6-FGFR4ΔSLBS cell line upon costimulation with FGF23 and αKlotho. In contrast, copious and intense punctate fluorescent spots appeared on the surface of L6-FGFR1cΔPLBS + FGFR4ΔSLBS co-expressing cells, which implies that an FGF23–FGFR1c–FGFR4–αKlotho–HS heterodimeric quaternary complex can form on the surface of live cells. These cell-based receptor complementation and hererodimerization data unequivocally confirm the asymmetry of our structurally deduced 1:2:1:1 FGF23–FGFR1c–αKlotho–HS signal transduction complex.

Because the αKlotho coreceptor does not directly participate in FGFRS recruitment, we suggested that asymmetric mode of receptor dimerization revealed by our FGF23–FGFR–αKlotho–HS cryo-EM structures may also be relevant to paracrine FGFs. To test this conjecture, we studied the impacts of asymmetric FGFRP–FGFRS dimer interface mutations on the abilities of FGFR1c and FGFR2b to mediate paracrine FGF signalling. These two FGFR isoforms were chosen because of their overlapping and unique ligand-binding specificity/promiscuity profile (Extended Data Fig. 5d). FGFR1c responds to paracrine FGF1 (a pan-FGFR ligand) and FGF4, whereas FGFR2b mediates the actions of FGF1, FGF3, FGF7, FGF10 and FGF22. For FGFR2b studies, we generated L6 cell lines expressing either wild-type (FGFR2bWT) or FGFR2b mutants (that is, FGFR2bE250A, FGFR2bR255A, FGFR2bI257A and FGFR2bY281A) analogous to the FGFR1c mutants mentioned above. Both FGFR1c and FGFR2b mutants were impaired in their capacity to undergo ligand-induced tyrosine trans auto-phosphorylation, which was also reciprocated in reduced PLCγ1 and FRS2α phosphorylation (Extended Data Fig. 6).

Next, we carried out receptor complementation and heterodimerization assays as was done for FGF23. For FGFR2b complementation study, we established L6-FGFR2bΔSLBS, L6-FGFR2bΔPLBS and L6-FGFR2bΔSLBS + FGFR2bΔPLBS cell lines corresponding to FGFR1c cell lines used for FGF23 study. In response to FGF1 or FGF4 stimulation, cells expressing FGFR1cΔPLBS or FGFR1cΔSLBS alone failed to elicit any appreciable FGFR1c signalling whereas L6-FGFR1cΔSLBS + FGFR1cΔPLBS cells responded with robust FGFR1c activation and signalling (Fig. 5e,f). Likewise, FGF1, FGF3, FGF7 and FGF10 each induced FGFR activation and signalling only in L6-FGFR2bΔSLBS + FGFR2bΔPLBS co-expressors (Extended Data Fig. 7). Lastly, we studied the possibility of FGFR heterodimerization by paracrine FGFs by focusing on: (1) FGFR1c–FGFR4 and FGFR1b–FGFR2b heterodimerizations by FGF1; (2) FGFR1b–FGFR2b heterodimerization by FGF10; and (3) FGFR2b–FGFR3b heterodimerization by FGF3. For the FGFR1b–FGFR2b heterodimerization assay, we generated an L6 cell line expressing FGFR1bΔSLBS, equivalent to FGFR2bΔSLBS. For FGF2b–FGFR3b heterodimerization by FGF3, we used wild-type FGFR3b (FGFR3bWT) as the ΔPLBS equivalent because this isoform naturally does not respond to FGF3. FGF1 failed to activate FGFR signalling in FGFR1cΔPLBS and FGFR4ΔSLBS cell lines. However, strong FGFR signalling was seen in the FGFR1cΔPLBS + FGFR4ΔSLBS co-expressing cell line in response to FGF1 stimulation (Fig. 5g,h). Likewise, both FGF1 and FGF10 induced robust FGFR activation/signalling only in the FGFR1bΔSLBS + FGFR2bΔPLBS co-expressing cell line but not in the L6-FGFR1bΔSLBS and L6-FGFR2bΔPLBS cell lines (Extended Data Fig. 8a–c). Lastly, FGF3 provoked signalling in the FGFR2bΔSLBS + FGFR3bWT co-expressing cell line but not in the L6-FGFR2bΔSLBS and L6-FGFR3bWT cells (Extended Data Fig. 8d,e). Based on these extensive cell-based data we conclude that paracrine FGF signalling is mediated via HS-induced asymmetric 1:2 FGF–FGFR dimers, reminiscent of the HS- and Klotho-induced endocrine 1:2 FGF23–FGFR dimer (Extended Data Fig. 9).

The 1:2:1:1 FGF23–FGFR–αKlotho–HS asymmetric quaternary complex structures and supporting biochemical data presented in this manuscript reveal how Klotho and HS glycosaminoglycan coreceptors act in concert to promote asymmetric 1:2 endocrine FGF–FGFR dimerization necessary for receptor activation and hence FGF hormone signalling. In this model, Klotho coreceptors tether FGF hormone and its primary receptor together and thus generate a stable endocrine FGF–FGFRP complex in the context of 1:1:1 FGF–FGFRP–Klotho ternary complexes. In doing so, Klotho coreceptors effectively offset the HS incompetency in stabilizing the endocrine FGF–FGFRP complex (Extended Data Fig. 9). The stabilized endocrine FGF–FGFRP complex is then assisted by a HS coreceptor to recruit a secondary FGFRS. Importantly, the Klotho coreceptor dependency restricts the site of action of FGF hormones to Klotho expressing tissues/organs (that is, kidney and parathyroid glands in the case of FGF23). Consistent with a lack of a direct role of Klotho in FGFRS recruitment, we show that the asymmetric mode of receptor dimerization is also applicable to paracrine FGFs. Unlike FGF hormones, paracrine FGFs have substantial affinity for HS and hence can rely solely on HS as an obligatory coreceptor to both stably bind FGFRP and recruit FGFRS. Despite sharing structural similarity, Klotho and HS-induced endocrine 1:2 FGF–FGFR dimers are thermodynamically inferior to HS-induced paracrine 1:2 FGF–FGFR dimers. Specifically, owing to the weak HS binding affinity of the FGF hormone, FGFRS is bound less tightly in the endocrine 1:2 FGF–FGFR dimer, which accounts for the weaker receptor activation/signalling capacity of FGF hormones relative to paracrine FGFs as posited by our ‘threshold model’ for FGF signalling specificity38. Remarkably, the asymmetric receptor dimerization model is compatible with receptor heterodimerization, which is likely to serve as an additional mechanism to qualitatively and quantitatively fine-tune FGF signalling.

The ligation-independent In-Fusion HD cloning kit (no. 639648, Clontech) was used to construct neomycin and hygromycin resistant pEF1α-IRES-neo and pEF1α-IRES-hygro lentiviral vectors encoding wild-type full-length human FGFR2c, FGFR3c and FGFR4 according to the protocol previously described for the human FGFR1c lentiviral expression construct6. The pET-30a-based bacterial expression construct for N-terminally his-tagged human FGF23 (residues Tyr25 to Ile251) was described previously6. pHLsec expression vectors encoding the extracellular ligand-binding region (that is, D2–D3 region) of FGFR3c (residues Asp142 to Arg365; FGFR3cecto) and FGFR4 (residues Asp142 to Arg365; FGFR4ecto) were made following the same strategy described previously for the human FGFR1cecto (ref. 6). Single and multiple site mutations and truncations were introduced into expression constructs encoding the wild-type proteins using a Q5 site-directed mutagenesis kit (no. E0554S, New England Biolabs Inc.). The expression constructs were verified by restriction enzyme digestion and DNA sequencing.

To produce minimally glycosylated ectodomains of FGFR1c, 3c and 4, N-acetylglucosaminyltransferase I (GnTI−) deficient HEK293S cells were transiently transfected with respective pHLsec expression constructs via cationic polymer polyethyleneimine (PEI, no. 23966-1, Polysciences, Inc.) following a published protocol40. Then, 24 h posttransfection, tryptone N1 (TN1, catalogue no. 19553, Organotechnie) was added to the medium to promote protein expression. At day three, secreted FGFR ectodomains from 1 l of conditioned medium were captured on a heparin affinity HiTrap column (no. 17040703, GE Healthcare) and eluted with 20 column volume of salt gradient (0–2 M). Fractions containing FGFRecto proteins were pooled, concentrated to 5 ml and applied to a Superdex-75 gel filtration column (no. 28989333, GE Healthcare). FGFRecto proteins were eluted isocratically in 25 mM HEPES pH = 7.5 buffer containing 1 M NaCl. Wild-type and mutated FGF23 proteins were expressed in E. coli as inclusion bodies, refolded in vitro and purified to homogeneity using sequential cation exchange and SEC following an established protocol6. Secreted αKlothoecto was purified from conditioned media of a HEK293S GnTI− cell line stably expressing the entire extracellular domain of human αKlotho (residues Met1 to Ser981; αKlothoecto) using a heparin affinity HiTrap column followed by SOUCRE Q anion and Superdex 200 column chromatography, as described previously6.

FGF23–FGFR1c–αKlotho–HS, FGF23–FGFR3c–αKlotho–HS or FGF23–FGFR4–αKlotho–HS quaternary complexes were prepared by mixing FGF23 with one of the FGFR ectodomains, αKlothoecto and a heparin dodecasaccharide 12 (HO12, Iduron Ltd) using a 1:1:1:1 molar ratio. The mixtures were concentrated to approximately 5 mg ml−1, applied to a Superdex 200 column (no. 28989335, GE Healthcare) and eluted isocratically in 25 mM HEPES pH = 7.5 buffer containing 100 mM NaCl. Peak fractions were analysed by SDS–PAGE and top fractions containing the highest concentration and purity of the quaternary complex were used directly for grid preparation without further concentration to avoid protein aggregation. The final concentrations of FGF23–FGFR1c–αKlotho–HS, FGF23–FGFR3c–αKlotho–HS and FGF23–FGFR4–αKlotho–HS complexes for grid preparation were 1.5, 2.4 and 1.5 mg ml−1, respectively.

To prepare the cryo-EM grids, 2–3 μl of purified protein complex at approximately1.5–2.5 mg ml−1 was applied to glow discharged gold grid (UltrAuFoil). The grid was then blotted for 1–2 s under 0 or 1 force at 100% humidity using a Mark IV Vitrobot (FEI) before plunging into liquid ethane. Micrographs of the FGF23–FGFR1c–αKlotho–HS and FGF23–FGFR4–αKlotho–HS complexes were acquired on a Talos Arctica microscope with K2 direct electron detector at ×36,000 magnification (corresponding to 1.096 Å per pixel). Accumulated doses used were 50.37 e−/Å2 and 53.84 e−/Å2 for FGF23–FGFR1c–αKlotho–HS and FGF23–FGFR4–αKlotho–HS, respectively. Micrographs of the FGF23–FGFR3c–αKlotho–HS complex were collected on a Titan Krios microscope equipped with a K2 direct electron detector and an energy filter. The magnification used was ×130,000, with a pixel size of 1.048 Å, and an accumulated dose of 72.44 e–/Å2. Leginon41 was used to target the holes with 5–100 nm of ice thickness, resulting in 10,186, 6,409 and 16,602 micrographs being collected for each of three quaternary complexes.

WARP42 was used for motion correction and contrast transfer function estimation for all three cryo-EM datasets. Micrographs with an overall resolution worse than 5.5 Å were excluded. The final number of micrographs used were 9,501, 5,164 and 15,049, respectively, yielding more than one million particles for each complex. Particle stacks were then imported to cryoSPARC43 for two-dimensional classification, ab-initio reconstruction with three or four models and three-dimensional classification. Finally, 1,497,967 (FGF23–FGFR1c–αKlotho–HS), 291,540 (FGF23–FGFR3c–αKlotho–HS) and 856,877 (FGF23–FGFR4–αKlotho–HS) particles were used for heterogeneous refinement with C1 symmetry, resulting in 2.74, 3.20 and 3.03 Å resolutions, respectively. Components/domains from FGF23–FGFR1c–αKlotho X-ray structures (PDB: 5W21) were manually docked into cryo-EM density maps using Chimera44 and the rigid body was refined. Initial models were then adjusted in Coot45 and real-space refined in Phenix46. Refinement and model statistics are shown in Extended Data Table 1. Representative cryo-EM images, two-dimensional class averages and three-dimensional maps of each quaternary complex are shown in Extended Data Fig. 1.

The cryo-EM structure of the FGF23–FGFR1c–αKlotho–HS quaternary complex was solvated in a water box of 16 × 16 × 16 nm3. The CHARMM-GUI server was used to generate the configuration, topology47,48,49,50 and the parameter files with the CHARMM36m force field51. In addition to protein molecules, the simulation system included about 138,073 water molecules, 393 sodium and 393 chloride ions (mimicking the 150 mM NaCl present in the protein buffer), resulting in a total of 439,298 atoms. A 300 ns all-atom MD simulation trajectory was generated using GROMACS 2021 (ref. 52) at 303 K using a time step of 2 fs. The cubic periodic boundary condition was used during the simulations and the van der Waals interaction was switched off from 1 nm to 1.2 nm. The long-range electrostatic interactions were calculated using the particle mesh Ewald (PME) method. Energy minimization was carried out using the steepest descent algorithm, followed by a 0.4 ns constant particle number, volume and temperature (NVT) and a 20 ns constant particle number, pressure and temperature (NPT) equilibration simulation by gradually decreasing force restraints from 1000 kJ mol−1 nm−2 to 400 kJ mol−1 nm−2 (for the NVT stage) and 400 kJ mol−1 nm−2 to 40 kJ mol−1 nm−2 (for NPT stage). At the conclusion of the equilibration steps, all force restraints were removed and the MD simulation was performed in the NPT ensemble.

HEK293T cells (verified by a morphology check under microscope, mycoplasma negative in 4′,6-diamidino-2-phenylindole (DAPI)) were used for lentiviral vector packaging and production of high-titre viral particles. An L6 myoblast cell line (no. GNR 4, National Collection of Authenticated Cell Cultures) was used as the host for stable expression of full-length (transmembrane) human FGFR1c, FGFR2c, FGFR3c, FGFR4 and mutants thereof. L6 cells endogenously express HSPGs but are devoid of FGFRs and αKlotho coreceptor and hence are naturally non-responsive to FGF23. However, via controlled ectopic co-expression of cognate FGFRs and αKlotho or exogenous supplementation with soluble αKlothoecto, these cells can respond to FGF23 stimulation. Accordingly, L6 cells are excellent hosts for reconstitution studies of FGF23 signalling in a physiological environment. Both HEK293T and L6 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, no. C11995500BT, Gibco) supplemented with 10% fetal bovine serum (FBS, no. FSD500, ExCell Bio), 100 U ml−1 of Penicillin and 100 μg ml−1 Streptomycin (no. P1400, Solarbio). Viral packaging and generation of the recombinant lentivirus particles in HEK293T cells were carried out using published protocols33. For stable expression of individual wild-type or mutated FGFR cell lines, 2 × 105 L6 cells were plated in six-well cell culture dishes and infected with lentivirus particles encoding given FGFR in the presence of polybrene (5 μg ml−1; no. sc-134220, Santa Cruz Biotechnology). Stable transfectants were selected using G418 (0.5 mg ml−1, no. HY-17561, MedChemExpress) or hygromycin (8 μg ml−1, no. HY-B0490, MedChemExpress). For the FGFR1c+αKlothoTM co-expressing cell line, L6 cells stably expressing FGFR1cWT (resistant to G418) were infected with lentiviral particles encoding wild-type or mutated transmembrane αKlotho (αKlothoTM) and the co-expressing cells were selected using hygromycin (80 μg ml−1, no. HY-B0490, MedChemExpress).

For cell stimulation studies, parental and stably transfected L6 cells were seeded in 12-well cell culture plates at a density of 1 × 105 cells per well and maintained for 24 h. On the next day, the cells were rinsed three times with phosphate buffered saline (PBS) and then serum starved for 12 h and costimulated with FGF23WT and αKlothoecto for 5, 10, 20 and 40 min. For single time point stimulation, samples were harvested after 5 min.

After stimulation, cells were lysed and total lysates samples were analysed by western blotting, as previously described33. The following antibodies were used: phosphorylated FGFR (1:1000, no. 3471S, Cell Signaling Technology), phosphorylated FRS2α (1:1000, no. 3864S, Cell Signaling Technology), phosphorylated PLCγ1 (1:1000, no. 2821S, Cell Signaling Technology), phosphorylated ERK1/2 (1:1000, no. 4370S, Cell Signaling Technology), α-tubulin (1:20000, no. 66031-1-Ig, Proteintech), total-FGFR1 (1:1000, no. 9740S, Cell Signaling Technology), total-FGFR2 (1:1000, no. 23328S, Cell Signaling Technology), total-FGFR3 (1:1000, no. ab133644, Abcam), total-FGFR4 (1:1000, no. 8562S, Cell Signaling Technology), HRP conjugated goat anti-mouse IgG (H + L) (1:5000, no. SA00001-1, Proteintech), HRP conjugated goat anti-rabbit IgG(H + L) (1:5000, no. SA00001-2, Proteintech). Blots were developed using enhanced chemiluminescence reagents (no. P10300, NCM Biotech Laboratories) by the ChemiDoc XRS+ system (Bio-Rad) or Amersham ImageQuant 800 (GE).

Endoglycosidase H (Endo H) sensitivity was used to analyse potential impacts of ectodomain mutations on FGFR glycosylation/maturation and hence trafficking to the cell surface. In immunoblots, wild-type FGFRs migrate as a doublet of a major diffuse upper and a minor sharp lower band. The upper band represents the fully glycosylated mature FGFR, decorated with complex sugars that has passed the ER quality control and has been successfully trafficked to the cell surface. On the other hand, the faster migrating lower band is an incompletely processed high mannose form that is trapped in ER. Mutations affecting receptor maturation manifest in an increase in proportion of the faster migrating ER-resident band. The mannose-rich form is sensitive to Endo H which cleaves the bond between two N-acetylglucosamine (GlcNAc) subunits directly proximal to the asparagine residue. However, the fully glycosylated cell surface-resident band is resistant to Endo H. Accordingly, cell-surface abundance of FGFRs can be expressed as a ratio of Endo H-resistant fraction over the total receptor expression as determined by treating the receptor with PNGase F. This enzyme is an amidase that hydrolyzes the bond between the innermost GlcNAc and asparagine irrespective of complex sugar content and thus completely strips the FGFR from all its N-linked sugars. Accordingly, WT or mutant FGFR cell lines were lysed in an NP-40 lysis buffer (Biotime, no. P0013F, supplemented with 1 mM PMSF) for 15 min at 4 °C. First, 20 μg total protein (quantified by BCA assay) were denatured with glycoprotein denaturing buffer at 100 °C for 10 min and then treated with 500 units of Endo H (New England Biolabs, no. P0702S) or peptide-N-glycosidase F (PNGase F) (New England Biolabs, no. P0704S) following the manufacturer's instructions. Endo H- and PNGase F-treated samples were immunoblotted with FGFR isoform-specific antibodies, as detailed above.

The molecular mass of the SEC-purified FGF23–FGFR1c-αKlotho–HS quaternary complex was determined by multi-angle light scattering following the established protocol6. Before the experiment, at least 60 ml of degassed running buffer (25 mM HEPES pH 7.5 containing 150 mM NaCl) were passed through the system to equilibrate the column and establish steady baselines for light scattering and refractive index detectors. Then, 50 μl of purified FGF23–FGFR1c-αKlotho–HS quaternary complex (1.5 mg ml−1) was injected onto the Superdex 200 10/300 GL column and the eluent was continuously monitored at 280 nm absorbance, laser light scattering and refractive index at a flow rate of 0.5 ml min−1. As a control, 50 μl of a purified FGF23–FGFR-αKlotho ternary complex (1.5 mg ml−1) sample was analysed under the same condition. The experiments were performed at ambient temperature. Laser light scattering intensity and eluent refractive index values were used to derive molecular mass as implemented by the ASTRA software (Wyatt Technology Corp.).

Cells were seeded onto microscope cover glasses (no. WHB-12-CS-LC, WHB) placed inside 12-well cell culture dishes at 1 × 105 cells per well and allowed to adhere for 24 h. On the next day, cells were washed three times with PBS and serum starved for 12 h. Following costimulation with FGF23WT and αKlothoecto for 20 min, cells were washed three times with PBS and fixed with 4% paraformaldehyde for 30 min prior to PLA. The PLA reaction was performed using a Duolink PLA kit following the manufacturer's instructions (no. DUO92101, Sigma-Aldrich) and visualized via fluorescence microscopy. Briefly, slides were treated with blocking solution for 60 min at 37 °C, rinsed three times with wash buffer A and then incubated overnight at 4 °C with two different primary antibodies raised in two different species for each FGFR isoform of interest (FGFR1 (1:20, no. PA5-25979, ThermoFisher) from rabbit, FGFR1 (1:100, no. ab824, Abcam) from mouse, FGFR2 (1:100, no. 23328S, Cell Signaling Technology) from rabbit, FGFR2 (1:50, no. sc-6930, Santa Cruz Biotechnology) from mouse, FGFR3 (1:100, no. MA5-32620, ThermoFisher) from rabbit, FGFR3 (1:100, no. sc-13121, Santa Cruz Biotechnology) from mouse, FGFR4 (1:100, no. 8562S, Cell Signaling Technology) from rabbit, FGFR4 (1:100, no. sc-136988, Santa Cruz Biotechnology) from mouse). Following three rinses with wash buffer A, slides were incubated with oligo-linked secondary antibodies (Duolink anti-mouse minus and anti-rabbit plus) for 1 h at 37 °C. Slides were rinsed again with wash buffer A and immersed in ligase solution for 30 min at 37 °C, to allow formation of circular DNA, followed by incubation with polymerase solution for 100 min at 37 °C for rolling circle amplification in a dark room. Slides were rinsed twice with wash buffer B for 10 min each, followed by rinsing with a 100-fold dilution of buffer B for 1 min. For imaging analysis, slides were covered by coverslips using a minimal volume of Duolink PLA mounting medium containing DAPI. Slides were examined using a confocal laser scanning microscope (C2si, Nikon).

All statistical analyses were carried out using GraphPad Prism 8.0. For statistical analysis of immunoblotting data, densitometric values (determined using ImageJ) from three independent experiments were used. For statistical analysis of PLA data, a number of fluorescent dots and cells (counted manually) was used from six randomly chosen microscope fields from two biologically independent experiments. Processing of the western blotting and PLA data in Figs. 2c,d, 3b–d and 4b,c was done using two-way ANOVA, followed by Tukey. One-way ANOVA, followed by Tukey was applied to process the western blotting data in Extended Data Fig. 3. Protein purifications were repeated at least eight times yielding samples with comparable purity/quantity. Western blotting experiments were carried out in biological triplicates with similar results. PLA assays were repeated at least twice independently, with analogous results.

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Electron density maps and refined models for the FGF23–FGFR1c–αKlotho–HS (EMD-34075, PDB: 7YSH), FGF23–FGFR3c–αKlotho–HS (EMD-34082, PDB: 7YSU) and FGF23–FGFR4–αKlotho–HS (EMD-34084, PDB: 7YSW) quaternary complexes have been deposited in the Electron Microscopy Data Bank and will be released upon acceptance of the manuscript. Raw uncropped western blot images are compiled in Supplementary Fig. 1. Source data are provided with this paper.

Kliewer, S. A. & Mangelsdorf, D. J. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 29, 246–253 (2019).

Article CAS PubMed PubMed Central Google Scholar

Degirolamo, C., Sabba, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51–69 (2016).

Article CAS PubMed Google Scholar

Kuro-o, M. Klotho and betaKlotho. Adv Exp Med Biol 728, 25–40 (2012).

Article CAS PubMed Google Scholar

Razzaque, M. S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 5, 611–619 (2009).

Article CAS PubMed PubMed Central Google Scholar

Kuro, O. M. The Klotho proteins in health and disease. Nat. Rev. Nephrol. 15, 27–44 (2019).

Article Google Scholar

Chen, G. et al. alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling. Nature 553, 461–466 (2018).

Article ADS CAS PubMed PubMed Central Google Scholar

Itoh, N. & Ornitz, D. M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J. Biochem. 149, 121–130 (2011).

Article CAS PubMed Google Scholar

Itoh, N. & Ornitz, D. M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 20, 563–569 (2004).

Article CAS PubMed Google Scholar

Kharitonenkov, A. et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627–1635 (2005).

Article CAS PubMed PubMed Central Google Scholar

Cariello, M., Piglionica, M., Gadaleta, R. M. & Moschetta, A. The enterokine fibroblast growth factor 15/19 in bile acid metabolism. Handb. Exp. Pharmacol. 256, 73–93 (2019).

Article CAS PubMed Google Scholar

Wang, X. & Shapiro, J. I. Evolving concepts in the pathogenesis of uraemic cardiomyopathy. Nat. Rev. Nephrol. 15, 159–175 (2019).

Article PubMed Google Scholar

Reitman, M. L. FGF21 mimetic shows therapeutic promise. Cell Metab. 18, 307–309 (2013).

Article CAS PubMed PubMed Central Google Scholar

Zhao, Y., Dunbar, J. D. & Kharitonenkov, A. FGF21 as a therapeutic reagent. Adv. Exp. Med. Biol. 728, 214–228 (2012).

Article CAS PubMed Google Scholar

Kharitonenkov, A. & DiMarchi, R. FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends Endocrinol. Metab. 26, 608–617 (2015).

Article CAS PubMed Google Scholar

Gaich, G. et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 18, 333–340 (2013).

Article CAS PubMed Google Scholar

Samuel, V. T. & Shulman, G. I. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab. 27, 22–41 (2018).

Article CAS PubMed Google Scholar

Harrison, S. A. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 391, 1174–1185 (2018).

Article CAS PubMed Google Scholar

Dickson, I. NASH: Successful phase II trial of FGF19 analogue. Nat. Rev. Gastroenterol. Hepatol. 15, 256 (2018).

PubMed Google Scholar

Johnson, K. et al. Therapeutic effects of FGF23 c-tail Fc in a murine preclinical model of X-linked hypophosphatemia via the selective modulation of phosphate reabsorption. J. Bone Miner. Res. 32, 2062–2073 (2017).

Article CAS PubMed Google Scholar

Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).

Article CAS PubMed PubMed Central Google Scholar

Katoh, M. Fibroblast growth factor receptors as treatment targets in clinical oncology. Nat. Rev. Clin. Oncol. 16, 105–122 (2019).

Article CAS PubMed Google Scholar

Yeh, B. K. et al. Structural basis by which alternative splicing confers specificity in fibroblast growth factor receptors. Proc. Natl Acad. Sci. USA 100, 2266–2271 (2003).

Article ADS CAS PubMed PubMed Central Google Scholar

Olsen, S. K. et al. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev 20, 185–198 (2006).

Article CAS PubMed PubMed Central Google Scholar

Liu, Y. et al. Regulation of receptor binding specificity of FGF9 by an autoinhibitory homodimerization. Structure 25, 1325–1336 e1323 (2017).

Article CAS PubMed PubMed Central Google Scholar

Sarrazin, S., Lamanna, W. C. & Esko, J. D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 3, a004952 (2011).

Article PubMed PubMed Central Google Scholar

Schlessinger, J. et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743–750 (2000).

Article CAS PubMed Google Scholar

Chen, L. et al. Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation. Nat. Chem. Biol. 16, 267–277 (2020).

Article ADS CAS PubMed PubMed Central Google Scholar

Goetz, R. et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 27, 3417–3428 (2007).

Article CAS PubMed PubMed Central Google Scholar

Yu, X. et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146, 4647–4656 (2005).

Article CAS PubMed Google Scholar

Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774 (2006).

Article ADS CAS PubMed Google Scholar

Ito, S. et al. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 115, 2202–2208 (2005).

Article CAS PubMed PubMed Central Google Scholar

Adams, A. C., Cheng, C. C., Coskun, T. & Kharitonenkov, A. FGF21 requires betaklotho to act in vivo. PLoS ONE 7, e49977 (2012).

Article ADS CAS PubMed PubMed Central Google Scholar

Kharitonenkov, A. et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J. Cell. Physiol. 215, 1–7 (2008).

Article CAS PubMed Google Scholar

Kurosu, H. et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282, 26687–26695 (2007).

Article CAS PubMed Google Scholar

Goetz, R. et al. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol. Cell. Biol. 32, 1944–1954 (2012).

Article CAS PubMed PubMed Central Google Scholar

Imura, A. et al. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 565, 143–147 (2004).

Article CAS PubMed Google Scholar

Bloch, L. et al. Klotho is a substrate for alpha-, beta- and gamma-secretase. FEBS Lett. 583, 3221–3224 (2009).

Article CAS PubMed PubMed Central Google Scholar

Zinkle, A. & Mohammadi, M. A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. F1000Res. 7, 872 (2018).

Article Google Scholar

Patstone, G. & Maher, P. Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors. J. Biol. Chem. 271, 3343–3346 (1996).

Article CAS PubMed Google Scholar

Aricescu, A. R., Lu, W. & Jones, E. Y. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243–1250 (2006).

Article PubMed Google Scholar

Suloway, C. et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41–60 (2005).

Article CAS PubMed Google Scholar

Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146–1152 (2019).

Article CAS PubMed PubMed Central Google Scholar

Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).

Article CAS PubMed Google Scholar

Pettersen, E. F. et al. UCSF Chimera – a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

Article CAS PubMed Google Scholar

Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).

Article PubMed Google Scholar

Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).

Article CAS PubMed PubMed Central Google Scholar

Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859–1865 (2008).

Article CAS PubMed Google Scholar

Jo, S., Lim, J. B., Klauda, J. B. & Im, W. CHARMM-GUI membrane builder for mixed bilayers and its application to yeast membranes. Biophys. J. 97, 50–58 (2009).

Article ADS CAS PubMed PubMed Central Google Scholar

Wu, E. L. et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004 (2014).

Article CAS PubMed PubMed Central Google Scholar

Lee, J. et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J. Chem. Theory Comput. 12, 405–413 (2016).

Article CAS PubMed Google Scholar

Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71–73 (2017).

Article CAS PubMed Google Scholar

Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2, 19–25 (2015).

Article ADS Google Scholar

Download references

Financial support was provided by the National Key R&D Program of China (2017YFA0506000 to X.L.), National Natural Science Foundation of China (82073705 & 82273842 to G.C., 82103999 to L.C., 81930108 to G.L.), Oujiang laboratory startup fund (OJQD2022007 to M.M.), Kungpeng Action Plan award (to M.M.), Natural Science Funding of Zhejiang Province (LR22H300002 to G.C., LQ22H300007 to L.C.), Wenzhou Major Scientific and Technological Innovation Project (ZY2021023 to G.C.), Qianjiang Talent Plan of Zhejiang (QJD1902016 to G.C.) and Wenzhou Institute (UCAS) startup fund (WIUCASQD2021043, to Y.W.).

These authors contributed equally: Lingfeng Chen, Lili Fu, Jingchuan Sun, Zhiqiang Huang, Mingzhen Fang

Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China

Lingfeng Chen, Lili Fu, Jingchuan Sun, Zhiqiang Huang, Mingzhen Fang, Xin Liu, Junliang Lu, Zixiang Pan, Yang Wang, Xiaokun Li, Gaozhi Chen & Moosa Mohammadi

School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, China

Lingfeng Chen & Guang Liang

Institute of Cell Growth Factor, Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision, and Brain Health), Wenzhou, China

Lili Fu, Zhiqiang Huang, Mingzhen Fang, Xin Liu, Junliang Lu, Zixiang Pan, Gaozhi Chen & Moosa Mohammadi

State Key Laboratory for Macromolecule Drugs and Large-scale Preparation, Wenzhou Medical University, Wenzhou, China

Lili Fu & Xiaokun Li

Laboratory of Cell Fate Control, School of Life Sciences, Westlake University, Hangzhou, China

Jingchuan Sun

Department of Physiology and Cellular Biophysics, Columbia University Irving Medical Center, New York, NY, USA

Allen Zinkle

Center of Biomedical Physics, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, China

Yang Wang

National Engineering Research Center of Cell Growth Factor Drugs and Protein Biologics, Wenzhou Medical University, Wenzhou, China

Xiaokun Li

Institute of chronic kidney disease, Wenzhou Medical University, Wenzhou, China

Gaozhi Chen

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

L.C. expressed, purified and prepared the quaternary complexes, carried out the size-exclusion chromatography–multi-angle light scattering analysis and prepared the structural figures. L.C. and J.S. prepared the cryo-EM grids, and collected and processed the images. A.Z. expressed and purified FGFR ectodomains. L.F. generated the mammalian expression constructs. J.L. expressed the mutant FGF23 proteins. L.F., Z.H., M.F., X.L., Z.P. and G.C. generated western blotting and PLA data and prepared the related figures. Y.W. generated MD simulation data. M.M. conceived the project, built and analysed the structural models and wrote the manuscript. All authors participated in discussion and revision of the manuscript.

Correspondence to Xiaokun Li, Gaozhi Chen or Moosa Mohammadi.

The authors declare no competing interests.

Nature thanks Makoto Kuro-o and the other, anonymous, reviewers(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Image processing workflow for the FGF23-FGFR-αKlotho-HS quaternary complex containing FGFR1c (left), FGFR3c (middle) or FGFR4 (right) as the receptor component. Gold-standard Fourier shell correlation (GSFSC) show global resolutions of 2.74, 3.20, and 3.03 Å for FGF23-FGFR1c-αKlotho-HS, FGF23-FGFR3c-αKlotho-HS, and FGF23-FGFR4-αKlotho-HS quaternary complexes, respectively.

A, Cartoon representation of the cryo-EM structure of the 1:2:1:1 FGF23-FGFR-αKlotho-HS quaternary complex in four different orientations related by 90° rotation along the vertical axis. The asymmetric quaternary complex has an average dimension of 130 Å × 100 Å × 55 Å. The proximity of membrane insertion points of FGFR chains (~25 Å apart) would be conducive to the formation of an asymmetric A-loop trans-phosphorylating dimer of intracellular kinase domain27. FGF23, αKlotho and HS are shown in orange, blue and magenta, respectively. Primary receptor (FGFRP) and secondary receptor (FGFRS) are shown in pale green and cyan. Dashed lines denote residues 172–182 of FGF23, the linker between FGF23's trefoil core and its distal αKlotho binding site, which could not be built due to lack of interpretable electron density. This region does not interact with either αKlotho or FGFR and is likely disordered/flexible. Notably, this region harbors the regulatory subtilisin-like proprotein convertase (SPC) site,176RHT178R179/S180AE182, which includes a furin type protease cleavage site (R179), an O-glycosylation site (T178) and a serine phosphorylation site (S180). Three enzymes namely GalNAc-T3(N-acetylgalactosaminyltransferase3), Fam20C (the family with sequence similarity 20, member C), and a yet to be discovered furin type protease converge on this site to regulate FGF23 processing. The high flexibility of this region is likely necessary for the action of these enzymes. B, FGF23 signaling is strictly αKlotho dependent. L6-FGFR1cWT cells were treated with increasing concentrations of recombinant FGF23WT alone, in combination with soluble αKlotho or left untreated. Whole cell lysates immunoblotted as in Fig. 2c. Note that even supra pharmacological concentrations (as high as 10 micromolar) of FGF23WT fails to activate FGFR1c signaling. However, when co-treated with soluble αKlotho, as little as 10 nM FGF23 induces a robust FGFR1c activation. Experiments were performed in biological triplicates with similar results. C, Superimposition of X-ray structure of the FGF23–FGFR1c–αKlotho ternary complex (PDB ID: 5W21, colored in green) onto the corresponding FGF23–FGFR1cP–αKlotho portion within the cryo-EM structure of 1:2:1:1 FGF23-FGFR1c-αKlotho-HS quaternary complex (colored in pink) shows high degree of similarity (RM)D of 1.16 Å].

a, Denatured lysates from L6-FGFR1cWT, L6-FGFR1cK175Q/K177Q (FGFR1cΔHBS1), L6-FGFR1cK207Q/R209Q (FGFR1cΔHBS2), and L6-FGFR1cK175Q/K177Q/K207Q/R209Q (FGFR1cΔHBS1+2) cells were incubated with Endoglycosidase H (Endo H) or Peptide-N-Glycosidase F (PNGase F) or left untreated. Samples were immunoblotted with FGFR1c isoform-specific antibody. Immunoblotting data were quantitated as described in the Methods section and are presented as the mean ± SD. b–d, Denatured lysates from L6 cell lines stably expressing FGFR1cWT, its four Site 2 (FGFR1cE249A, FGFR1cR254A, FGFR1cI256A, FGFR1cY280A) and one Site 1 (FGFR1cA170D/A171D/S219D) mutants (b), wild-type FGFR3c (FGFR3cWT) or its four Site 2 mutants (FGFR3cE247A, FGFR3cR252A, FGFR3cI254A, FGFR3cY278A) (c), wild-type FGFR4 (FGFR4WT) or its four Site 2 mutants (E243A, R248A, I250A, Y274A) (d) were treated with Endo H, PNGase F or left untreated. Samples were immunoblotted with FGFR isoform-specific antibodies as indicated. Experiments were performed in biological triplicates with similar results. Quantitation was done as described in the Methods section and are presented as the mean ± S.D. P values were determined by One-way ANOVA followed by Tukey's multiple comparisons post hoc test.

Source data

A, Left and Center: Cartoon representations of the FGF23-FGFRS and FGFRP-αKlotho components of the quaternary complex shown in the orientation obtained via alignment of D2 domains of FGFRS and FGFRP. Right: Superimposition of FGF23-FGFRS and FGFRP-αKlotho components via aligning receptors’ D3 domains. Note that FGF23 N-terminus and αKlotho RBA engage the equivalent hydrophobic grooves in D3 of FGFRS and FGFRP chains. b–d, FGF23 N-terminus undergoes a major conformational change in FGF23–FGFR–αKlotho–HS quaternary complexes. Cartoon and surface (only for FGF23 component) representation of HS-free ternary complex (that is, X-ray structure) (b) and HS-induced quaternary complex (that is, cryo-EM structures) (c) in the same orientation obtained via alignment of their FGF23 chains. (d) Cartoon representation of an overlay between FGF23-FGFR1c from FGF23–FGFR1c–αKlotho ternary complex and FGF23-FGFR1cP from quaternary complex via FGF23 alignment. Note the dramatic difference in the positions of FGF23 N-terminus between the two structures. e, Electron densities of FGF23 N-terminus in cryo-EM structures of FGF23–FGFR1c–αKlotho–HS quaternary complexes at the indicated contour levels. Note that the electron densities for FGF23 N-terminus are weak and patchy. f–i, MD simulation data show that FGF23 N-terminus engages D3 of FGFR1cS. f, Left: Cartoon representation of the cryo-EM structure of FGF23-FGFR1c-αKlotho-HS quaternary complex. FGF23, FGFR1cP, FGFR1cS and αKlotho are in orange, green, cyan, and blue, respectively. Right: Zoomed-in view of the boxed region (left) showing conformational progression of the N-terminal tail of FGF23 (that is, Y25 to W36) and D3 of FGFR1cS in a 300 ns MD simulation trajectory denoted by a color transition from the orange (0 ns) to blue (300 ns) in 60 ns intervals. FGF23 N-terminus interacts with the three stranded βC: βF: βG sheet in FGFR1cS D3 domain. g-h, Changes in RMSD (g) and Root Mean Square Fluctuation (RMSF, h), respectively, of N-terminal tail of FGF23 during MD simulation. Note that RMSD of N-terminal residues of FGF23 stabilized around 4 Å after 120 ns. Importantly, residues at the distal and proximal ends of FGF23 N-terminus exhibited largest and smallest RMSF, respectively, mirroring their respective cryo-EM electron densities (compare e and h). i, Changes in the distances of four selected contact pairs (Y25–L342S, S29–R254S, L31–A259S and L32–I256S) between N-terminal residues of FGF23 and residues in D3 of FGFR1cS. The distances of Y25–L342S, L31–A259S, and L32–I256S hydrophobic residue pairs fluctuated around 5 Å indicative of formation of hydrophobic contacts between these residue pairs. Likewise, the pairwise distance for S29-R254S fluctuated around 4 Å after 120 ns indicative of hydrogen bonding between side chains of this residue pair.

a-b, Rationale for receptor complementation assay. Center: Cartoon/surface representation of the FGF23–FGFR1c–αKlotho–HS quaternary complex in two orientations related by 180° rotation around Y axis. Circles denote approximate circumferences of ligand binding sites in primary and secondary receptors selected for mutagenesis. a, Left: expanded view of circled region on the secondary receptor showing that Ile-203 and Ser-223 of FGFR1cS engage in hydrophobic and hydrogen bonding contacts with residues in FGF23's core. Right: expanded view of circled region on the primary receptor showing that Ala-167 and Val-248 of FGFR1cP engage in highly conserved hydrophobic contacts with Tyr-124 and Leu-158 of FGF23, respectively. Additionally, Ala-167 also makes a hydrogen bond with Tyr-124. b, Left, expanded view of the circled region on the primary receptor showing that the corresponding Ile-203 and Ser-223 in FGFR1cP are solvent exposed. Thus, an engineered FGFR1cI203E/S223E molecule (i.e., FGFR1cΔSLBS) should preserve the ability to act as primary receptor despite losing the capacity to function as secondary receptor. Right, expanded view of the circled region on secondary receptor showing that the corresponding Ala-167 and Val-248 in FGFR1cS do not play any role in the quaternary complex formation and are solvent exposed. Thus, an engineered FGFR1cA167D/V248D mutant (i.e., FGFR1cΔPLBS) is predicted to lose the ability to function as primary receptor but could still act as secondary receptor. c, Demonstration of receptor complementation between FGFR1cΔSLBS and FGFR1cΔPLBS and between FGFR4ΔSLBS and FGFR1cΔPLBS via PLA. Representative fluorescent microscopy fields of stable cell lines subjected to PLA are shown. Scale bar,10 μm. Experiments were performed at least two times biological repeat with similar results. d, Structure-based sequence alignment of ligand binding regions (i.e., D2, D2-D3 linker and D3) of all seven FGFR isoforms. As a guide, a schematic representation of a prototypical FGFR is shown and its various domains are labeled. The C-terminal half of D3 which undergoes alternative splicing in FGFR1-FGFR3 is highlighted in dark blue. Note that the unspliced N-terminal half of D3 is conserved between b and c isoforms. Secondary structure elements are provided on the top of alignment. The HS interacting residues are all localized within D2 domain and are colored in magenta. Residues mediating the FGF23-FGFRP and αKlotho-FGFRP interfaces are colored yellow and green, respectively. Note that residues mediating direct FGFRP-FGFRS contacts (in light blue) are fully conserved amongst all seven isoforms. As for the FGF23-FGFRS interface (in orange), only D2 residues that contact FGF23's core, are conserved between the seven isoforms. However, two hydrophobic D3 residues that interact with FGF23 N-terminus at the FGF23-FGFRS interface are conserved only in FGFR1c-3c and FGFR4 (indicated by black arrow heads). In FGFR1b-3b, these residues, which overlap with binding site for RBA of αKlotho, are replaced by charged residues. Hydrophobicity of D3 groove FGFR1b-3b is further disrupted by the presence of a unique N-linked glycosylation site within their D3 grooves (denoted by a red box). In FGFR2c, a key conserved hydrophobic residue is replaced by a charged Lys-296 (underlined in red) which likely accounts for the inability of FGFR2c to bind αKlotho.

a, Immunoblots of whole cell extracts from untreated or FGF-treated (1 nM) untransfected and transfected L6 cell lines stably expressing FGFR1cWT, FGFR1cE249A, FGFR1cR254A, FGFR1cI256A, or FGFR1cY280A probed with antibodies against phosphorylated FGFR, PLCγ1 and FRS2α. b, Immunoblots of whole cell extracts from untreated or FGF-treated (1 nM for FGF1 and 2 nM for FGF3/7/10/22) treated untransfectedand transfected L6 cell lines stably expressing FGFR2bWT, FGFR2bE250A, FGFR2bR255A, FGFR2bI257A, or FGFR2bY281A probed with FGFR2b isoform specific antibody (top) or phosphospecific antibodies as in panel a. Experiments were performed in biological triplicates with similar results.

a, Schematic diagram showing that in response to paracrine FGF1/3/7/10 and HS, FGFR2bΔSLBS and FGFR2bΔPLBS can complement each other and form 1:1:1:1 FGF-FGFR2bΔSLBS-FGFR2bΔPLBS-HS asymmetric signaling complexes. b-e, Demonstration of receptor complementation between FGFR2bΔSLBS and FGFR2bΔPLBS via westernblotting. L6 cell lines singly expressing FGFR2bWT, FGFR2bΔPLBS, FGFR2bΔSLBS, or co-expressing FGFR2bΔSLBS with FGFR2bΔPLBS were treated with 1 nM FGF1 (b), 2 nM FGF3 (c), 2 nM FGF7 (d), or 2 nM FGF10 (e) for increasing time intervals, and total cell extracts were immunoblotted as indicated. Experiments were performed in biological triplicates with similar results.

a, Schematic diagram showing that FGF1 or FGF10, HS, and FGFR1bΔSLBS (serving as primary receptor) form stable complexes which subsequently recruit FGFR2bΔPLBS as secondary receptor. b-c, L6 cell lines singly expressing FGFR1bWT or FGFR1bΔSLBS, or co-expressing FGFR1bΔSLBS + FGFR2bΔPLBS were treated with 1 nM FGF1 (b) or 2 nM FGF10 (c) for increasing time intervals and cell extracts were immunoblotted. d, Schematic diagram showing that in the presence of HS, FGF3 and FGFR2bΔSLBS (serving as primary receptor) form a stable complex and subsequently recruit FGFR3bWT as secondary receptor. e, L6 cell lines expressing FGFR3bWT alone or co-expressing it with FGFR2bΔSLBS were treated with 2 nM FGF3 for increasing time intervals and cell extracts were immunoblotted. Experiments were performed in biological triplicates with similar results.

a, Due to FGF hormone's weak HS binding affinity, HS alone is incompetent in stabilizing the endocrine FGF-FGFR complex and inducing sustained asymmetric receptor dimerization/activation. Blurring and loose association are used to emphasize the unstable/transient nature of putative FGF-FGFR-HS ternary complex and physiologically inconsequential receptor dimerization/activation. b, Membrane bound Klotho co-receptor simultaneously engages FGFR's D3 domain and FGF's C-terminal tail thereby stabilizing the endocrine FGF-FGFR complex within a ternary complex. In so doing, Klotho co-receptor effectively compensates for HS incompetency in stabilizing binary endocrine FGF-FGFR complex. HS is now in position to recruit a second FGFR to the stabilized binary complex thus inducing asymmetric dimerization. Nevertheless, due to FGF hormone's weak HS binding affinity, Klotho and HS-induced endocrine 1:2 FGF-FGFR dimers are still inferior to HS-induced paracrine 1:2 FGF-FGFR dimers in terms of longevity/stability (indicated by slight blurring of FGFRS in b). c, Due to their high HS binding affinities, paracrine FGFs can rely on HS as the sole co-receptor to stably bind primary FGFR and recruit a secondary FGFR, thereby inducing formation of rigid and long-lived asymmetric receptor dimers.

Supplementary Figs. 1–4 and Tables 1–2.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Chen, L., Fu, L., Sun, J. et al. Structural basis for FGF hormone signalling. Nature (2023). https://doi.org/10.1038/s41586-023-06155-9

Download citation

Received: 06 September 2022

Accepted: 02 May 2023

Published: 07 June 2023

DOI: https://doi.org/10.1038/s41586-023-06155-9

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.